Drug Type Small molecule drug |
Synonyms JRF 104, JRF104, XH-30002 |
Target |
Action inhibitors |
Mechanism AXL inhibitors(AXL receptor tyrosine kinase inhibitors), CDK4 inhibitors(Cyclin-dependent kinase 4 inhibitors), CDK6 inhibitors(Cyclin-dependent kinase 6 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 01 Dec 2020 | |
| Esophageal Carcinoma | Preclinical | China | 15 Aug 2024 | |
| Acute Myeloid Leukemia | Preclinical | China | 15 Aug 2020 |





